Wednesday, June 10, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 117 of 200 Β· By data quality, then INN

  1. arginine

    LYSAKARE

    EMA: approved

    V03AF11
  2. arimoclomol

    MIPLYFFA

    EMA: application withdrawn

    N07
  3. asciminib

    SCEMBLIX Novartis Pharmaceuticals

    EMA: approved Β· TGA: approved

    L01EA06
  4. asparaginase

    GRASPA

    FDA: approved Β· EMA: approved

    L01XX02
  5. ataluren

    TRANSLARNA

    EMA: unknown

    M09AX03
  6. atazanavir

    REYATAZ Bristol-Myers Squibb Australia Pty Ltd

    EMA: approved Β· TGA: approved

    J05AE08
  7. atosiban

    ATOSIBAN SUN

    EMA: approved

    G02CX01
  8. aumolertinib

    AUMSEQA

    EMA: approved Β· NMPA: clinical trials

    L01EB
  9. autologous cartilage-derived articular chondrocytes, in-vitro expanded

    JELRIX

    EMA: application withdrawn

    M09AX02
  10. autologous cd34+ cells encoding arsa gene

    LIBMELDY

    EMA: approved

    N07
  11. autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence

    STRIMVELIS

    EMA: approved

    L03
  12. autologous glioma tumor cell lysates (inactivated)

    SITOIGANAP

    EMA: application withdrawn

    L01XX
  13. autologous human chondrocytes in vitro expanded

    ARTOBEND

    EMA: application withdrawn

    M09AX02
  14. autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)

    PROVENGE

    EMA: withdrawn

    L03AX17
  15. avacincaptad pegol

    IZELVAY

    EMA: application withdrawn

    S01XA32
  16. avalglucosidase alfa

    NEXVIADYME

    EMA: approved Β· PMDA: approved

    A16
  17. avatrombopag

    DOPTELET Swedish Orphan Biovitrum Pty Ltd

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    B02BX
  18. axicabtagene ciloleucel

    YESCARTA

    EMA: approved

    L01XX70
  19. bamlanivimab

    BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19

    EMA: withdrawn from rolling review

  20. bardoxolone methyl

    IMBARKYD

    EMA: application withdrawn

  21. bazedoxifene

    CONBRIZA

    EMA: approved

    G03XC02
  22. beclometasone

    TRYDONIS

    EMA: approved

    R03AL09
  23. bedaquiline

    SIRTURO

    EMA: approved

    J04AK05
  24. begelomab

    BEGEDINA

    EMA: application withdrawn

    L04AA35

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.